1. Allison, A. C., and Byars, N. E. (1991). Immunological adjuvants: Desirable properties and side-effects. Mol. Immunol.28,279–284.
2. CBER. (2000). Guidance for Industry Considerations for Reproductive Toxicity Studies for Preventive Vaccines for Infectious Disease Indications.
3. Chang, P. Y., Sheets, R. L., Shapiro, S., Hargus, S., and Gruber, M. (2003). Vaccine pre-clinical toxicology testing. Available at: http://www.niaid.nih.gov/daids/vaccine/Science/VRTT/00_Main.htm
4. Department of Health & Human Services, Food & Drug Administration. (2005). Revocation of status of specific products; group A streptococcus; direct final rule. Fed. Regist.70,72197–72199.
5. Martin, J. E., Enama, M. E., Koup, R. A., Bailer, R. T., Moodie, Z., Roederer, M., Nabel, G. J., and Graham, B. S. (2005). VRC 004: Safety and Immunogenicity of a Multiclade HIV-1 DNA Vaccine in Healthy Uninfected Adults (VRC-HIVDNA009-00-VP). J. Allergy. Clin. Immunol.115,892.